Atorvastatin + Atorvastatin

Phase 1Completed
0 watching 0 views this week๐Ÿ’ค Quiet
32
Hype Score

Development Stage

โœ“
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pediatric Heterozygous Hypercholesterolemia

Conditions

Pediatric Heterozygous Hypercholesterolemia

Trial Timeline

Dec 1, 2008 โ†’ May 1, 2009

About Atorvastatin + Atorvastatin

Atorvastatin + Atorvastatin is a phase 1 stage product being developed by Pfizer for Pediatric Heterozygous Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00739999. Target conditions include Pediatric Heterozygous Hypercholesterolemia.

Hype Score Breakdown

Clinical
10
Activity
5
Company
9
Novelty
3
Community
2

Clinical Trials (5)

NCT IDPhaseStatus
NCT01033058ApprovedUNKNOWN
NCT00739999Phase 1Completed
NCT00728988ApprovedCompleted
NCT00917579ApprovedCompleted
NCT00644670ApprovedCompleted